Theravance to Webcast 2013 Annual Meeting of Stockholders on April 24, 2013
(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/18/13 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2013 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Wednesday, April 24, 2013.
An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the audio feed live via the internet may do so by visiting the company's web site at . To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.
A replay of the 2013 Annual Meeting of Stockholders will be available on the company's web site for 30 days through May 24, 2013. A telephone replay will also be available through 11:59 p.m. Eastern Daylight Time on May 1, 2013 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 21880057.
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: RELVAR™ or BREO™ ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at .
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.
RELVAR™ or BREO™ ELLIPTA™ (FF/VI) and ANORO™ ELLIPTA™ (UMEC/VI) are investigational medicines and are not currently approved anywhere in the world. RELVAR™, BREO™, ANORO™ and ELLIPTA™ are trademarks of the GlaxoSmithKline group of companies. The use of these brand names has not yet been approved by any regulatory authority.
(THRX-G)
Michael W. Aguiar
Senior Vice President and Chief Financial Officer
650-808-4100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.04.2013 - 14:05 Uhr
Sprache: Deutsch
News-ID 1218042
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SOUTH SAN FRANCISCO, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 116 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theravance to Webcast 2013 Annual Meeting of Stockholders on April 24, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
Theravance, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
